BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY

摘要

Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, bispecific antibodies are disclosed that are able to engage T-cells to destroy TAG-72-expressing malignant cells. Disclosed are bispecific antibodies that are able to engage T-cells to destroy TAG-72-expressing malignant cells. The antibodies can be engineered from fusion polypeptides comprising 1) variable domains of antibodies that specifically bind an immune cell antigen and 2) variable domains of antibodies that specifically bind TAG-72.

主权项

1. A fusion polypeptide comprising the following formula:
VLI-VHI--VLT---VHT, VHI-VLI--VLT---VHT, VLI-VHI--VHT---VLT, or VHI-VLI--VLT---VHT, wherein “VHT” is a heavy chain variable domain specific for TAG-72; wherein “VLT” is a light chain variable domain specific for TAG-72; wherein “VLI” is a light chain variable domain specific for an immune cell antigen; wherein “VHI” is a heavy chain variable domain specific for the immune cell antigen; wherein “-” consists of a peptide linker or a peptide bond; wherein “--” consists of a peptide linker or a peptide bond; and wherein “---” consists of a peptide linker comprising the amino acid sequence SEQ ID NO:5.